PRISM is accepting submissions for our next screen May 27 – June 13!
DMSO-soluble small molecules (single agent and combination format) and single agent antibodies, ADCs, and growth-inhibiting cytokines can now be submitted for our ~930 cancer cell line screen.
PRISM rapidly screens a wide range of drugs across more than 900 human cancer cell line models using a high-throughput, multiplexed approach.
Large-scale cancer cell line screening is critical to oncology drug discovery and development to better understand how drugs work. Traditional phenotypic screening tests only one cell line at a time using a lot of resources and taking a lot of time. Generating data for a small subset of cell lines results in an incomplete understanding of your drug.
Using PRISM, we accelerate the screening process by employing a novel DNA barcode-based approach that enables simultaneous high-throughput viability analysis of over 900 cell lines from over 45 cancer subtypes. Our extensive cell line collection captures the diversity of human cancers to provide a comprehensive evaluation of oncology drug candidates.
Hundreds of collaborators are partnering with PRISM including over 30 biotech and pharmaceutical companies.
Find out how PRISM can help accelerate your research
Learn about our collaborative working model and requirements for screening
Contact us to learn more about PRISM
